University of Nottingham
VC Fund
Nottingham, United Kingdom
University of Nottingham is a VC fund in Nottingham focused on Biotechnology and Health Care. The University of Nottingham shares many of the characteristics of the world’s great universities. However, they are distinct not only in their key strengths but in how their many strengths combine: they are financially secure, campus based and comprehensive; they are research-led and recruit top students and staff from around the world; they arecommitted to internationalising all their core activities so their students can have a valuable and enjoyable experience that prepares them well for the rest of their intellectual, professional and personal lives.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries University of Nottingham invests in
Stages University of Nottingham invests in
Countries University of Nottingham invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alistair Speidel
|
|||
Martin Baumers
|
|||
Paul Russell
|
|||
Simon Hart
|
|||
Andrew Hopkinson
|
|||
| See all 12 contacts → | |||
Investment Focus
Industry
- Biotechnology 8 (50%)
- Health Care 3 (19%)
- Pharmaceutical 2 (13%)
- Health Diagnostics 2 (13%)
- Industrial Engineering 2 (13%)
Stage
- Seed 6 (38%)
- Venture - Series Unknown 4 (25%)
- Grant 2 (13%)
- Funding Round 2 (13%)
- Series A 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alistair Speidel
Research Fellow
|
Research Fellow | Total investments: 0 | Find email | |
|
Martin Baumers
Assistant Professor in Additive Manufacturing Management
|
Assistant Professor in Additive Manufacturing Management | Total investments: 0 | Find email | |
|
Paul Russell
Chairman Strategic Advisory Board School of Physics & Astronomy
|
Chairman Strategic Advisory Board School of Physics & Astronomy | Total investments: 0 | Find email | |
|
Simon Hart
Honorary Associate Professor in Power Conversion for Transportation Electrification
|
Honorary Associate Professor in Power Conversion for Transportation Electrification | Total investments: 0 | Find email | |
|
Andrew Hopkinson
Principal Research Fellow
|
Principal Research Fellow | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TextureJet
|
TextureJet designs, develops, and deploys machine tools and technologies for surface processing in high value manufacturing. | Venture - Series Unknown / Jul 01, 2026 | |
NuVision
|
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham. | $6.5M / Venture - Series Unknown / Feb 05, 2026 | |
Promethean Particles
|
Promethean Particles design, develop and manufacture inorganic nanoparticle dispersions to our customer’s specifications. Promethean uses continuous hydrothermal synthesis to make the optimum product for each application and backs this up with a brand new multi-ton scale nanoparticle manufacturing plant (in excess of 1000 tons per year). We covermany industry needs such as printed electronics (enabling flexible circuitry, 3D printing etc.), nanocomposites, catalysts, MOFs, healthcare etc. In addition, we offer a feasibility study service to tailor a custom made solution for the specific requirements of a customer. Promethean is not only unique due its multi nano-material production capacities, the company possesses significant know-how, a successful patented technology and flexibility to offer the right solution to its partners. | $10.3M / Series A / Aug 14, 2024 | |
PeptiMatrix
|
We are a team of matrix biologists, cancer scientists, toxicologists, and biomaterial engineers who have worked together to develop an innovative, animal-free solution for 3D cell culture.We have done this with the support of the NC3Rs, BBSRC, and EPSRC. By combining the skills and expertise of individuals across a broad range of scientificbackgrounds we are able to develop technologies that address a variety of unmet challenges in 3D in vitro modelling.Our mission is to provide researchers a better way to model development and disease that is more reproducible, reliable, and ethical.To learn more, visit www.peptimatrix.com | $435.9K / Grant / Jul 04, 2023 | |
National Biofilms Innovation Centre
|
The National Biofilms Innovation Centre (NBIC) is the central hub where academia, industry, government, and public policy come together to tackle the grand challenges biofilms present, impacting ~$5 trillion in global economic activity, from food and health to ships, clean water and energy. Funded by the BBSRC, Innovate UK and Hartree Centre, ourmission is to establish a network of research and innovation capacity to catalyse partnerships with industry to achieve breakthrough innovations and impact – from industry products and solutions to services and spinouts. We aim to bring together researchers and industry to explore unmet needs and exchange ideas, problems and solutions through roadmaps, workshops and conferences. We plan to invest in future scientists through our PhD and Post-Doc programs, and entrepreneurial training, to grow their expertise, help them better understand the commercial environment and encourage new start-ups. | $27.8M / Grant / Nov 22, 2022 | |
BlueSkeye AI
|
BlueSkeye AI is using technology that can comprehend mood and mental wellbeing to approach healthcare from an AI perspective. | $3.7M / Seed / Oct 21, 2022 | |
PBD Biotech
|
PBD Biotech has developed the only rapid, sensitive test to detect live mycobacteria, which are responsible for bovine TB and Johne’s Disease, both economically disastrous.Trials have demonstrated the effectiveness of Actiphage, which can detect mycobacteria at low levels in blood or milk within six hours. The test has applications in qualitycontrol of dairy products, and could revolutionise the way bovine TB and other livestock diseases are identified and managed.Since the company established, it has gained funding, UK government approval for exceptional private use, proven efficacy in the field, opened an office in Canada and trials are currently underway on farms, in hospital and with national institutions around the world. | $2.7M / Venture - Series Unknown / Oct 17, 2022 | |
Alevin Therapeutics
|
Alevin Therapeutics is creating breakthrough approaches to safe and effective medicines for patients with life-threatening diseases. | Seed / Jul 29, 2022 | |
Cheesecake Energy
|
Cheesecake Energy is developing advanced thermal and compressed air energy systems to store energy from intermittent renewables, turning them into reliable power on-demand. | Venture - Series Unknown / May 06, 2020 | |
|
NuVision
|
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham. | $1.8M / Sep 12, 2019 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does University of Nottingham invest in?
University of Nottingham invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Venture - Series Unknown stage. Most of the 16 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact University of Nottingham?
Public channels for University of Nottingham include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at University of Nottingham?
The team at University of Nottingham includes Alistair Speidel (Research Fellow), Martin Baumers (Assistant Professor in Additive Manufacturing Management) and Paul Russell (Chairman Strategic Advisory Board School of Physics & Astronomy), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
